3,511 results found

Despite the fact that this is the third ruling the WTO has made against the United States’ meat-labelling laws in five years, the U.S. is appealing this most recent decision.

This article originally appeared in Food in Canada and is republished with the permission of the publisher.

Earlier this year, the legislative framework surrounding the provision of medical marijuana in Canada underwent significant change.

On August 29, 2017 Apotex filed a motion with the Supreme Court of Canada, requesting a rehearing of the appeal and an amendment of the corresponding judgment in which the Supreme Court held that the promise doctrine is not the appropriate standard for assessing utility and that AstraZeneca's 653 Patent is valid (2017 SCC 36;

Health Canada has announced its intent to consult on "plain packaging" for tobacco products. Full details have yet to be released, but it is likely that only the brand name could appear on packaging.

The Court accepted that where Parliament has comprehensively legislated in a particular area, as it has in respect to patents, it was reasonable to infer that it did not intend recovery to extend beyond those embodied in the regime.

Justice Noël writing for the Court of Appeal disagreed with Apotex’s appeal of Justice Hughes’ decision to grant an order of prohibition with respect of the NOC for Apo-brimonidine-timop until expiry of the relevant patent.

It is common for manufacturers to "highlight" ingredients or flavours in food using words, pictures, or graphics, such as "made with real fruit" and/or a picture of berries.

On January 28, 2014, the Federal Court issued a decision under the "Patented Medicines (Notice of Compliance) Regulations" involving the patent for the drug celecoxib.

Health Canada recently published a notice regarding the Guidance Document: Patented Medicines (Notice of Compliance) Regulations.

The Federal Court of Appeal has dismissed Lilly's appeals of judgments that held Canadian Patent No. 2,371,684 claims invalid.

In this proceeding, Teva and Apotex brought motions under the PM(NOC) Regulations arguing that a patent listed against ViiV's KIVEXA drug was not eligible for purposes of paragraph 4(2)(a) of the Regulations.

On October 27, 2020, the Patented Medicine Prices Review Board released the National Drug Prescription Utilization System's analytic study of the Canadian oncology market for 2010 to 2019.

On June 20, 2023 the Patented Medicine Prices Review Board (PMPRB) invited stakeholders to comment on its proposed amendment for conducting interim price reviews on New Medicines...

The Federal Court has reaffirmed and clarified how a pharmaceutical brand company should respond to a generic company's motion to strike an application for abuse of process...

The following reports on two court decisions addressing procedure under these amendments.

On November 18, the Association of European Businesses held a briefing in Russia, in which the head of the Russia Patent and Trademark Office (Rospatent)